Gene-Editing Therapies: The Cure for Genetic Diseases?

How is science responding to genetic diseases? A novel technique in gene-editing therapies brings treatment that has precision and efficiency.

By Julian Lau

Have you visited the doctor, feeling nervous as they mention the many possible genetic diseases—cystic fibrosis, hemophilia—that could affect anyone? Researchers at the University of Texas at Austin have now discovered a groundbreaking method to edit human genes, offering the potential to treat multiple genetic diseases at once.

The future of gene editing

The researchers used retrons—genetic elements found in bacteria that protect them from viral infection—in their pioneering work. They demonstrated that retron gene therapy can correct scoliosis-causing mutations in zebrafish embryos. This marks the first time retrons have successfully repaired a gene-causing mutation in a vertebrate. 

In the human body, genetic material such as DNA is constantly synthesized as we grow, eat, and carry out daily functions. However, during this process, errors in the forms of gene mutations can occur, sometimes leading to the development of genetic diseases. Current research aims to prevent these conditions by developing gene-editing methods that can efficiently and effectively fix any mutations that appear. Unfortunately, existing gene-editing therapies are heavily limited to targeting only one or two mutations at a time, restricting their use across the broader population. 

RELATED: Read more about gene mutations in Ongoing Human Evolution Revealed in Data

Building on previous gene-editing therapies

The newly developed retron-based gene therapy enables scientists to replace large stretches of mutated genetic material with healthy genetic material. The advantage that this retron-based therapy holds over existing gene therapies is its versatility. This retron-based therapy can fix mutations over a large stretch of genetic material, no matter the individual, rather than at a single point in the genetic material. This broader applicability also makes retron-based therapies more cost-effective to develop, increasing their availability in the market and to the public. 

Another key advantage over traditional gene-editing therapies lies in the delivery method. Retrons in this therapy are delivered as RNA encased in a lipid nanoparticle. This is a safe and precise delivery system. The nanoparticles are specifically engineered in a manner that can deliver the retrons directly to the appropriate site of mutations, making the repair of genetic material very efficient.

This is not the first time that researchers have tried to use retrons in gene-editing therapies. Previous attempts have been unsuccessful, with those therapies only able to insert new genetic material into about 1.5 percent of the cells it targeted. In contrast, researchers at UT Austin have achieved successful insertion in 30 percent of cells it targeted. This result is a dramatic improvement, with potential for even greater efficiency as this technology advances.

Bringing the fight to a molecular level

The first significant application of this retron-based therapy will target cystic fibrosis, a disease caused by mutations in the CFTR gene that leads to chronic respiratory infections and lung damage. Current gene therapies are ineffective for about 10 percent of cystic fibrosis patients, so researchers hope that the newly developed retron-based therapy could finally reach these patients. The UT Austin team has recently received grants from several nonprofit organizations to further their cystic fibrosis research, adding momentum to the development of this promising therapy.

Although this retron-based therapy has yet to be tested in human patients, it will be critical to monitor this therapy as it passes through clinical trials and FDA approval. As researchers continue to uncover the full potential of their retron-based therapy, we may soon see their application expand to a wide range of genetic diseases. This breakthrough represents a significant step forward in improving quality of life, showcasing the transformative power of scientific innovation and curiosity. 

This study was published in the peer-reviewed journal Nature Biotechnology. 

Reference

Buffington, J. D., Kuo, H.-C., Hu, K., Chang, Y.-C., Javanmardi, K., Voigt, B., Li, Y.-R., Little, M. E., Devanathan, S. K., Xhemalçe, B., Gray, R. S., & Finkelstein, I. J. (2025). Discovery and engineering of retrons for precise genome editing. Nature Biotechnology. https://doi.org/10.1038/s41587-025-02879-3 

Featured image of DNA by Maxometr on Wikimedia Commons, licensed under CC BY-SA 4.0.

The information contained in this article is for informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.